ariV schreef op 21 mei 2021 20:21:
[...]
Dat fase drie zal wel niet kloppen indd.maar dit gaat gewoon over de uitbreiding van de basel trial in zuid Amerika. Wacht even waar janssen&Janssen mee komen.
Zit gewoon lekker te googelen en klik steeds door van het 1 naar het ander.
Zal wel weer allang achterhaald zijn maar is prothix niks voor Pharming om over te nemen kan er niet veel over vinden, behalve dat ze een link hebben met ArgenX en dat de founder Rene Verdonk bij Pharming gewerkt heeft en dat ze in hetzelfde spectrum als pharming bezig zijn/waren.
Prothix is a market driven biotech company dedicated to the development of recombinant therapeutic proteins that address the medical need of patients with inflammatory and coagulation disorders.
The company utilizes a so-called niche-buster strategy to capitalize its product portfolio. Following this strategy, the company only invests in products that initially can be developed for small niche markets, for which competition is low or absent, to be developed later for other indications in block buster markets.
All products developed by Prothix are monoclonal antibody products.
1) PRO-01 is a novel anticoagulant drug for thrombo-embolic disorders. The competitive edge of this product is safety. In contrast to current anticoagulants extensive pharmacodynamic monitoring is not necessary because risk for bleeding side effects of PRO-01 is minimal.
2) PRO-02 is a complement inhibitor and a novel anti-inflammatory product for antibody-mediated diseases and prevention of ischemia re-perfusion damage. Several potential leads that block complement-mediated cytotoxicity of human cells sensitized with anti-HLA antibodies have been generated by Prothix.
3) PRO-03 is a novel pro-coagulant product for bleeding disorders. PRO-03 will be first developed for hemophilia patients with inhibitors. PRO-03 has a unique mechanism of action among other pro-coagulant drugs such as NovoSeven, and in contrast to other pro-coagulant products can be given for prophylaxis.
4) PRO-04 is a novel anti-inflammatory compound that inhibits bradykinin formation. The compound has a unique mechanism of action and is developed for the treatment of different forms of angioedema.